Company Filing History:
Years Active: 2008
Title: The Innovations of Kenneth Santora
Introduction
Kenneth Santora is a prominent inventor based in Kensington, Maryland, recognized for his significant contributions to cancer research. His innovative work revolves around the development of anti-CD30 antibodies, which serve as a vital tool in the field of immunotherapy for certain types of cancers, including Hodgkin’s disease and specific leukemias.
Latest Patents
Kenneth Santora holds one patent titled "Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins." This invention addresses a crucial aspect of the CD30 receptor, which is expressed on cancerous cells. The patent focuses on the discovery that a residual extracellular stalk of CD30 remains after cleavage, presenting a new target for immunotoxins. The antibodies described in this patent bind to the CD30 stalk, as well as to epitopes that are destroyed when CD30 is cleaved, providing a pathway for developing effective cancer treatments. The antibodies formed through this invention are particularly suitable for creating disulfide-stabilized Fv immunoconjugates, which can label or inhibit the growth of CD30-expressing cancer cells and activate complement-dependent cytotoxicity.
Career Highlights
Kenneth Santora's inventive journey is significantly shaped by his affiliation with the Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services. His research has played a pivotal role in advancing the understanding and treatment of cancers associated with the CD30 receptor.
Collaborations
Throughout his career, Kenneth has collaborated with esteemed colleagues Ira H. Pastan and Satoshi Nagata, enhancing the research and development of immunotherapeutic strategies targeting CD30. These partnerships have undoubtedly enriched his contributions to the field, bringing together a wealth of knowledge and expertise.
Conclusion
Kenneth Santora's work exemplifies the critical importance of innovation in medical research, particularly in developing targeted therapies for cancer treatment. His patent on anti-CD30 antibodies marks a significant advancement in immunotherapy, highlighting how inventive thinking can lead to transformative solutions in healthcare. Through his collaborations and dedication to research, Kenneth continues to pave the way for future innovations in the fight against cancer.